Markets PLRX

Pliant Therapeutics: Bexotegrast INTEGRIS-PSC Interim Data Surpasses Expectations

September 26, 2023 — 08:35 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Pliant Therapeutics, Inc. (PLRX) reported positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis. The trial met primary and secondary endpoints showing that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose.

"The INTEGRIS-PSC interim data has surpassed our expectations, providing hope to patients with PSC who currently have no approved therapeutic options available to them," said Éric Lefebvre, Chief Medical Officer of Pliant.

The company noted that it has recently completed enrollment of the high-dose 320 mg dose cohort of the INTEGRIS-PSC Phase 2a trial. Interim 12-week data is expected in the first quarter of 2024, with 24-week data anticipated in mid-2024.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
PLRX

Latest Articles
Data is currently not available